laboratoires pierre fabre
laboratoires pierre fabre is majority owned by a government - recognized public - interest foundation (by decree dated 6 april 1999): the pierre fabre foundation .
the foundation now holds 86% of the capital of pierre fabre sa, through the holding company pierre fabre participations (pfp) .
the institut curie (paris, france) and the laboratoires pierre fabre s. a. (castres, france) entered a renwable, one - year partnership to develop cancer immunotherapies against novel targets using the institute’s biological models. the institute and pierre fabre ...
laboratoires pierre fabre have thus embarked on a new and original artistic adventure in france. together with entreprisecontemporaine®, they went to international artists likely to embody the vision, energy and humanistic values of their founder .
on the occasion of the first anniversary of the death of their founder, laboratoires pierre fabre asked two internationally recognized visual artists and attached to france, the german sculptor stephan balkenhol and from chinese origin painter yan pei - ming, to pay tribute to the memory of mr. pierre fabre .
through the pierre fabre participations holding company, the pierre fabre foundation, a government - recognized public - interest foundation, owns 86% of pierre fabre laboratories. 7% of remaining shares are owned by company employees, and 7% are treasury stock .
division of experimental cancer research i, centre de recherche pierre fabre, castres, france .
the pierre fabre foundation’s priorities lie in investing in programs concerning: the training of pharmacists and health professionals .
2014: tribute to mr. pierre fabre | entreprise contemporaine® - enterprise + contemporary art = sense another way
the pierre fabre culture is based on a strong value system, which is shared by it employees around the world .
as pioneers in dermo - cosmetics, pierre fabre laboratories develop innovative solutions for the hygiene, care and beauty of skin, hair and scalp. with a portfolio of 7 brands, pierre fabre is the largest dermo - cosmetic laboratory on the french market, and the second largest worldwide .
pierre fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo - cosmetics. in 2016, pierre fabre dedicated almost 143 million euros to r & d, shared between oncology, the central nervous system, consumer health care, dermatology and dermo - cosmetics .
pierre fabre is the 3rd largest french pharmaceutical group. in 2013, its sales reached €2. 008 billion, with international revenues accounting for 56% . founded and still based in the south - west of france, pierre fabre currently has branches in 44 countries and distribution agreements in over 130 countries .
qumas, an accelrys company (nasdaq: accl), today announced that pierre fabre laboratories, a leading pharmaceutical and cosmetics company with headquarters in castres, france, has selected qumas doccompliance to manage and control quality documents across the entire company. the qumas compliance platform was selected after an extensive evaluation process conducted by members of the quality assurance and it teams at pierre fabre laboratories. the qumas solution will be rolled out to 3, 850 pierre fabre employees initially .
with 50 sites in france, mostly located in the south - west and subsidiaries in 44 countries worldwide, pierre fabre combines a strong local presence with international expansion .
pierre fabre laboratories, the second largest independent pharmaceutical group in france, achieved sales of over 2 billion euros in 2013, with international sales representing 56% in total .
convinced of the benefits provided by plants on health and beauty, pierre fabre laboratories have made research on plant substances a major focus of its activities for over 50 years .
the main aim of the pierre fabre foundation, a government - recognized public - interest organization, is to improve access to quality medication and care in the least developed and developing countries .
in 2008, mr. pierre fabre had already made a donation of the majority of his shares in the company to the foundation. he completed this donation by appointing the foundation as the sole legatee .
july 3rd, 4th and 5th will take place in castres the 12th edition of the e - health summer university. pierre fabre, a historical partner, will organize a hackathon, the ia santé challenge .
“we conducted a very thorough evaluation of a number of vendor solutions, ” commented pierre contreras, business project director for pierre fabre laboratories. “we were very impressed with the advanced features of doccompliance and its large reference base of companies across our industry, as well as the professionalism and responsiveness of the qumas team. ”
with brands such as avène, klorane, ducray, rené furterer, a - derma, galénic, naturactive, elgydium, eludril or drill, pierre fabre laboratories are market leaders when it comes to skin, hair and oral care products sold in french pharmacy channels. avène is marketed worldwide, and is the leading dermo - cosmetics brand in europe, japan and china. in oncology, pierre fabre achieves 90% of its revenues outside of its home country .
15 employees, representative of the main activities of the company and with various backgrounds, were invited to participate in the selection process. after a final presentation to the family and friends of mr. pierre fabre in march 2014, two artists were finally selected: yan pei - ming for a triptych painted portrait, which will be presented to employees on key sites of the company, and stephan balkenhol for a statue in polychrome bronze, installed on the site of the pierre fabre foundation .
in order to contribute to the preservation of plant resources while achieving its innovation and quality objectives, the group has set up a certified process for the responsible development of innovative, safe and effective plant - based key ingredients: pierre fabre botanical expertise .
pierre fabre is the 2nd largest dermo - cosmetics laboratory in the world and the 2nd largest private french pharmaceutical group. in 2017, it generated 2, 318 million euros in revenues, of which 62% came from its international business and 62% from its dermo - cosmetics division. pierre fabre, which has always been headquartered in the south - west of france, owns subsidiaries and offices in 47 countries, enjoys distribution agreements in over 130 countries and counts more than 13, 500 employees worldwide .
humanism, independence and sustainability pierre fabre laboratories have set up a unique shareholder structure to ensure its continuity and independence, while perpetuating the humanitarian values of its founder. the company is held in majority (65 %) by the pierre fabre foundation, recognized as a non - profit since 1999. contributing to health and well - being, advocating for pharmaceutical ethics in all we do, respecting biodiversity, or belonging to a foundation of public utility: our company has multiple facets that are also challenges for sustainable development .
pierre fabre laboratories provide pharmacists, health care professionals and patients with a large range of prescription and otc drugs in three main fields: family health (drill, pédi - relax, smoking cessation…), oral care (elgydium, inava…) and natural health (naturactive) .
the laboratory was established in the early 1960s by pierre fabre, a pharmacist in castres, a city located in the tarn, near toulouse (south - west of france). for the past 50 years, the company has pursued a development strategy focusing on the needs of patients .
through his company, moved in 50 years from a pharmacy in the city of castres to a pharmaceutical group operating globally, mr. pierre fabre will have built an original and daring oeuvre. deeply attached to the sense of beauty, full of great sensitivity for art, architecture and culture, he was a great sponsor that supported the major museums in the midi - pyrenees region and commissioned the architect roger taillibert, member of the institute, for the construction of several landmark buildings, including the centre for research and development pierre fabre located on the campus of toulouse oncopole .
covering all aspects of healthcare, from prescription drugs and otc products to dermo - cosmetics, pierre fabre laboratories employ over 10, 000 people worldwide. every year, the group allocates more than 17% of its drug revenues to r & d, focusing on three main areas: oncology, dermatology and neuropsychiatry .
the management of employee shareholdings is carried out by the supervisory board, which is composed of 6 members representing shareholders and 6 members representing the company. its chairman, by law a representative of the shareholders, sits on the board of directors of pierre fabre sa. in 2012, the french federation of employee share ownership honored pierre fabre laboratories with three of the six awards for employee shareholding: the grand prix de l' actionnariat‐salarié des sociétés non cotées (the grand prix of employee shareholding for unlisted companies), the grand prix de la qualité de l' information et de la formation des actionnaires‐salariés (the grand prix of information quality and training for employee shareholders), the grand prix des présidents d' associations (the grand prix of association presidents) .
“qumas provides pierre fabre with a scalable solution that will enable employees across all of its product sites to collaborate on quality assurance content and documents in a controlled, compliant and fully auditable manner, ” stated kevin o’leary, ceo for qumas. “we are delighted to be adding another leading french company to our client list, and plan to increase our client base in europe significantly this year. ”
each year, the group invests close to 20% of its sales in r & d, focusing on three key research areas: oncology, dermatology and neuropsychiatry. pierre fabre employs 1, 400 people in r & d, spread across five centers of excellence: toulouse (cytotoxic molecules and new targeted therapies, skin research, dermo - cosmetics), saint - julien - en - genevois (biotherapies and monoclonal antibodies in oncology) and castres (treatment of neuropsychiatric pathologies) .
qumas doccompliance provides pierre fabre laboratories with a complete web - based electronic document management system that enables users to create, manage, circulate and securely store all documents and content related to quality assurance and quality control across the company’s product portfolio. the platform fully supports electronic signatures as per the fda 21 cfr part 11 requirements and is configurable, allowing companies to mirror their organizational structures and practices. all of the compliance capabilities of the platform are accessed through myqumas, a user - friendly web - based interface .
since its creation in 1999, the foundation has mainly been involved in africa and asia, in the following countries: laos, cambodia, vietnam, madagascar, senegal, mali, benin, guinea and togo. the foundation is chaired by mr. pierre - yves revol. its board of directors has 14 members, 2 of whom are representatives of the french state, and who monitor the public interest mission for which the foundation is recognized as a public - interest organization .
afghanistan aland islands albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british indian ocean territory british virgin islands brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde caribbean netherlands cayman islands central african republic chad chile china christmas island cocos (keeling) islands colombia comoros congo (brazzaville) congo (kinshasa) cook islands costa rica croatia cuba curaçao cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands faroe islands fiji finland france french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guinea - bissau guyana haiti heard island and mcdonald islands honduras hong kong s. a. r. , china hungary iceland india indonesia iran iraq ireland isle of man israel italy ivory coast jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao s. a. r. , china macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk island northern mariana islands north korea norway oman pakistan palau palestinian territory panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russia rwanda saint barthélemy saint helena saint kitts and nevis saint lucia saint martin (french part) saint pierre and miquelon saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south georgia and the south sandwich islands south korea south sudan spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand timor - leste togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu u. s. virgin islands uganda ukraine united arab emirates united kingdom united states united states minor outlying islands uruguay uzbekistan vanuatu vatican venezuela vietnam wallis and futuna western sahara yemen zambia zimbabwe
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
antimitotic and tubulin - interacting properties of vinflunine, a novel fluorinated vinca alkaloid. - pubmed - ncbi
warning: the ncbi web site requires javascript to function. more ...
antimitotic and tubulin - interacting properties of vinflunine, a novel fluorinated vinca alkaloid .
kruczynski a 1, barret jm, etiévant c, colpaert f, fahy j, hill bt .
this study aimed to define the mechanism of action of vinflunine, a novel vinca alkaloid synthesised from vinorelbine using superacidic chemistry and characterised by superior in vivo activity to vinorelbine in preclinical tumour models. in vitro vinflunine cytotoxicity proved dependent on concentration and exposure duration, with ic50 values (72 - hr exposures) generally ranging from 60 - 300 nm. vinflunine induced g2 + m arrest, associated with mitotic accumulation and a concentration - dependent reduction of the microtubular network of interphase cells, accompanied by paracrystal formation. these effects, while comparable to those of vincristine, vinblastine or vinorelbine, were achieved with 3 - to 17 - fold higher vinflunine concentrations. however, vinflunine and the other vincas all inhibited microtubule assembly at micromolar concentrations. vinflunine, like vinblastine, vincristine and vinorelbine, appeared to interact at the vinca binding domain, as judged by proteolytic cleavage patterns, and induced tubulin structural changes favouring an inhibition of gtp hydrolysis. however, vinflunine did not prevent [ 3h ] vincristine binding to unassembled tubulin at concentrations < or = 100 microm, and only weakly inhibited binding of [ 3h ] vinblastine or [ 3h ] vinorelbine. indeed, specific binding of [ 3h ] vinflunine to tubulin was undetectable by centrifugal gel filtration. thus, the comparative capacities of these vincas to bind to or to interfere with their binding to tubulin could be classified as: vincristine > vinblastine > vinorelbine > vinflunine. by monitoring alkylation of sulfhydryl groups, differential effects on tubulin conformation were identified with vinflunine and vinorelbine acting similarly, yet distinctively from vinblastine and vincristine. overall, vinflunine appears to function as a definite inhibitor of tubulin assembly, while exhibiting quantitatively different tubulin binding properties to the classic vinca alkaloids .
welcome to our newsroom - get access to information and multimedia resources about bristol - myers squibb. current and archived releases and publications are available .
learn about our efforts, new goals and initiatives in the areas of philanthropy and sustainability .
array biopharma inc. (nasdaq: arry) said fda approved braftovi encorafenib in combination with mektovi binimetinib to treat braf v600 mutation - positive unresectable or metastatic melanoma. the company said the combo is now available, but declined to provide ...
technology: snps; plasma markers a plasma cfdna mutation on pi3kca could help predict resistance to combined inhibition of mek, cdk4 and cdk6 in nras - mutant melanoma. in samples from a patient with metastatic nras - mutant melanoma treated with ...
array biopharma inc. (nasdaq: arry) reported that binimetinib (mek162) plus encorafenib (lgx818) significantly improved median overall survival (os) compared to braf inhibitor zelboraf vemurafenib in the phase iii columbus trial to treat braf v600 mutation - positive melanoma... .
array biopharma inc. (nasdaq: arry) gained $ 2. 19 (16 %) to $ 16. 28 on tuesday after reporting that binimetinib (mek162) plus encorafenib (lgx818) significantly improved median overall survival compared to braf inhibitor zelboraf vemurafenib in the phase iii columbus ...
array biopharma inc. (nasdaq: arry) reported updated response data for a combination regimen of encorafenib (lgx818), binimetinib (mek162) and erbitux cetuximab in the safety lead - in portion of the phase iii beacon crc trial to treat braf ...
array biopharma inc. (nasdaq: arry) gained $ 2. 42 (19 %) to $ 15. 56 monday after reporting updated response data for a combination regimen of encorafenib (lgx818), binimetinib (mek162) and erbitux cetuximab in the safety lead - in portion of the phase ...
cancer play five prime therapeutics inc. (nasdaq: fprx) promoted aron knickerbocker to president and ceo from coo, effective jan. 1, 2018. he succeeds lewis williams, who will become executive chairman. cell therapy company cytosen therapeutics inc... .
html public
- / / w3c / / dtd xhtml + rdfa 1. 0 / / en
urltoken
you would like to sell or license a product, to reach a co - marketing agreement, or to form an alliance or a joint - venture in pharmaceuticals, consumer health care, oral care or dermo - cosmetics, and you are looking for a partner with expertise over the full pharmaceutical value chain .
you are a biotech, a start - up or a research lab (private or public) specialized in oncology, onco - dermatology or dermatology, and you are looking for a partner to speed up the development process of new products currently at advanced preclinical stage or at early clinical stage .
you wish to develop new plant - based products in the pharmaceutical, nutrition or agri - food sectors, gain access to our collection of over 15, 000 plant samples and benefit from our expertise .
you are looking for a partner recognized by international drugs and health agencies to develop and produce active ingredients, pharmaceutical lozenges, injectables, cytotoxic agents or immune - conjugates .
in order to do this, we design and develop consumer and patient inspired innovative solutions that contribute to people' s well - being, from health to beauty. we achieve this by cooperating with health - care professionals, our trusted partners worldwide, by drawing relentless inspiration from nature and plants, and by placing pharmaceutical ethics at the very heart of our operations .
the company has a unique governance structure to ensure its continuity and independence, while perpetuating the humanist values of its founder .
our revenues exceeded €2. 3 billion. this is growth of 1. 6% compared to 2016, propelled by our international business, which grew by over 3% .
a company owned by its employees and by a foundation in a way that protects our business against surprise speculation: this is my goal to ensure its continuity .
7. 8% of the remaining shares are held by the employees (through the employee stock ownership plan set up in 2005) and 6. 2% is held as treasury stock (shares held by the company itself) .
the fight against sickle - cell anemia, a serious genetic illness that mainly affects the african continent .
launched in france in 2005, the employee shareholder plan has been open to employees of our 6 main european subsidiaries since 2008. the total scope covered by the plan thus encompasses over 85% of the group' s staff. currently 91% of all employees able to benefit from the plan are shareholders. they hold 6. 7% of the company' s capital (2011 figures) .
the plan constitutes a major element of the way in which our capital is organized. it also contributes towards the development of a new corporate culture, in which each employee is even more closely associated with the life and growth of the company. financial information targeting employees is proposed regularly, while training programs in the economics of the company are organized. this plan also allows employees to increase their savings: any payments made can be supplemented by the company in accordance with a matching system .
for the best experience on our site, be sure to turn on javascript in your browser .
our activities cover all aspects of health care, from prescription drugs and dermo - cosmetics to family health products. we have subsidiaries in over 40 countries, market products in over 130 countries, and employ 10, 000 people worldwide .
avène is the leading dermo - cosmetic brand in europe, japan and china .
qumas is the leader in enterprise compliance solutions with more than 270 global customer deployments and two decades of experience helping companies in highly regulated industries. qumas is a gold microsoft partner, and provides the qumas compliance platform on sharepoint 2010, documentum, oracle or sql. for more information, visit urltoken .
qumas is an accelrys company. accelrys (nasdaq: accl), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. the industry - leading accelrys enterprise platform provides a broad, flexible scientific foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, qa / qc and manufacturing phases of product development. accelrys offers capabilities in scientific data management, modeling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health & safety and operations intelligence for customers in science - driven industries. using accelrys technology, scientific innovators can access, organize, analyze and share data in unprecedented ways across the research, laboratory and manufacturing continuum, ultimately enhancing innovation, improving productivity and compliance, reducing costs and accelerating product development from research to manufacturing .
accelrys solutions are used by more than 2, 000 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. headquartered in san diego, calif. , accelrys employs approximately 225 full - time phd scientists. for more information about accelrys, visit urltoken .
a social enterprise, we connect and inform 900, 000 + development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people .
this site is operated by a business or businesses owned by informa plc and all copyright resides with them. informa plc' s registered office is 5 howick place, london sw1p 1wg. registered in england and wales. number 8860726 .
ashwagandha advantage - delivering clinical research and market insights on this powerful adaptogenic. click here for more .
dosage delivery forms are now a critical part of chemistry for creating inventive sports nutrition products forward - looking ...
puffed snacks and probiotics are leading the growth in the on - the ...
we may wish to contact you regarding future events and products including natural products insider digital, please uncheck this box if you do not wish to receive these updates .
natural products insider digital carefully selected third party partners may wish to contact you. please uncheck this box if you do not wish to receive these communications .
you may withdraw your consent to receive any of our communications at any time. you understand that your information will be used in accordance with the privacy policy .
enter your email above to receive messages about offerings by informa, its brands, affiliates and / or third - party partners, consistent with informa' s privacy statement .
healthy aging with bioactive collagen peptides®. not all are the same. - infographic
paul frantellizzi, ceo of good superfoods, shares his experiences developing and launching efficacious products with ksm - 66 ashwagandha.
laboratoires pierre fabre is a french multinational pharmaceutical and cosmetics company . the company had a consolidated turnover of 1.978 billion euros in 2012 ( including 54 % international ) . it is headquartered in the city of castres , midi-pyrénées , france . founded in 1962 by pierre fabre ( 1926-2013 ) , the company is present in over 130 countries . laboratories pierre fabre had approximately 10,000 employees in 2012 , 33 % of whom are internationally based , while the remaining 6,700 employees were based in france . the company 's business activity is focused on research , development , manufacturing and marketing of cosmetics , prescription medicines and family health products . pharmaceuticals and phytotherapy represent 47 % of turnover , whereas cosmetics represent 53 % ( percentages of 2012 turnover ) . pierre fabre is best known for its vinorelbine ( navelbine ) , an anticancer drug of the vinca alkaloid class . they also developed vinflunine , a fluorinated vinca alkaloid derivative available in australia for " advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen . " olivier bohuon , now chief executive of smith & nephew , was chief executive from september 2010 to april 2011 . 
laboratoires pierre fabre is a french multinational pharmaceutical and cosmetics company. the company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international). it is headquartered in the city of castres, midi-pyrénées, france. founded in 1962 by pierre fabre (1926-2013), the company is present in over 130 countries. laboratories pierre fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in france. the company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover). pierre fabre is best known for its vinorelbine (navelbine), an anticancer drug of the vinca alkaloid class. they also developed vinflunine, a fluorinated vinca alkaloid derivative available in australia for " advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen. " olivier bohuon, now chief executive of smith & nephew, was chief executive from september 2010 to april 2011.
laboratoires pierre fabre is a french multinational pharmaceutical and cosmetics company. the company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international). it is headquartered in the city of castres, midi-pyrénées, france. founded in 1962 by pierre fabre (1926-2013), the company is present in over 130 countries. laboratories pierre fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in france. the company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover). pierre fabre is best known for its vinorelbine (navelbine), an anticancer drug of the vinca alkaloid class. they also developed vinflunine, a fluorinated vinca alkaloid derivative available in australia for " advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen. " olivier bohuon, now chief executive of smith & nephew, was chief executive from september 2010 to april 2011.